Sharetreck – Tracking Genomic Investments & clinical trials for HIV.

Glaucoma, the second leading cause of blindness worldwide, is characterized by progressive damage to the optic nerve, often associated with elevated intraocular pressure (IOP). It affects millions globally and poses a significant public health concern. In this blog post, we explore notable individuals with glaucoma, genetic causes, cutting-edge research, current treatment options, market trends, and global impact statistics. The cost for glaucoma treatment ranges from $650 to $2500 per year for medications, $1000 to $2000 for laser treatment, and around $11000 for incisional surgery. Current research indicates that while CRISPR shows promise, more studies are needed to confirm its effectiveness in reversing glaucoma.

Famous People with Glaucoma

1. Ray Charles

• The legendary musician and composer Ray Charles was diagnosed with glaucoma at a young age. He lost his sight by the age of seven due to the disease. Despite his blindness, Charles had a highly successful career in music, becoming an iconic figure in American culture.

2. Bono

• The lead singer of the rock band U2, Bono, revealed in an interview that he has glaucoma. He explained that he has been managing the condition for over two decades, which is why he often wears tinted glasses.

Genetic Causes: MYOC Mutations and Glaucoma

MYOC mutations are the most common genetic cause of glaucoma, affecting approximately 150,000 people in the United States. These mutations are autosomal dominant, meaning one copy of the mutated gene from a parent can cause the disease. MYOC mutations lead to an earlier onset and more rapid progression of glaucoma.

Pathophysiology:

• Mutations in MYOC result in misfolded myocilin protein aggregates in the endoplasmic reticulum (ER) of trabecular meshwork (TM) cells.
• Dysfunctional TM leads to impaired drainage of aqueous humor, increasing IOP and causing optic nerve damage.

Innovations in Treatment: CRISPR/Cas9 and LNP Delivery

CRISPR/Cas9 Technology:

• CRISPR/Cas9 can precisely target and modify specific genetic sequences.
• Researchers use CRISPR/Cas9 to knock out MYOC expression in the TM, reversing ER stress, restoring TM function, and reducing IOP.
• Preclinical models show that knocking out MYOC has been effective, with no adverse effects on normal ocular function.

Lipid Nanoparticle (LNP) Delivery:

• LNPs can deliver CRISPR/Cas9 components to TM cells. In vivo studies show a significant reduction of the target protein in mouse models.
• Approximately 200 LNPs were tested in vitro, with 40 selected for in vivo testing. LNP-mediated delivery achieved around 90% reduction of α-smooth actin (α-SMA) protein expression in mouse TM, serving as a surrogate marker.

Current Standard of Care for Glaucoma

Medications:

• Medications to reduce IOP are often used as the first line of treatment.

Procedures:

• Laser trabeculoplasty to improve aqueous humor outflow.
• Surgical interventions, including trabeculectomy and drainage implants, to create new drainage pathways or enhance existing ones.

The Global Glaucoma Treatment Market

Market Valuation and Growth:

• In 2022, the global glaucoma treatment market was worth approximately US$ 5.7 billion.
• From 2023 to 2033, the market is projected to grow at a CAGR of 3.18%.
• By 2033, the market is expected to reach around US$ 8.0 billion.

Types of Glaucoma

Open-Angle Glaucoma:

• The most common type, characterized by gradual vision loss without apparent symptoms initially.

Angle-Closure Glaucoma:

• Less common, occurs suddenly with symptoms like eye pain, visual disturbances, and nausea.

Causes and Risk Factors:

• High Eye Pressure: Elevated IOP is a major risk factor, damaging the optic nerve.
• Other Factors: Includes age-related macular degeneration, cataracts, diabetic retinopathy, and uncorrected refractive errors.

Global Impact and Statistics

According to the World Health Organization (WHO):

• About 4.5 million people had glaucoma in 2019.
• As of 2022, more than 80 million people live with glaucoma.
• The number of glaucoma patients is anticipated to exceed 111 million by 2040.

Conclusion

The combined insights into MYOC mutations, the potential of CRISPR therapeutics, and the global glaucoma treatment market highlight the significant progress and ongoing efforts in combating this leading cause of blindness. The market is set for steady growth, driven by advancements in genetic research and therapeutic technologies, offering hope for improved management and potential cures for glaucoma.